-
Consumer Insights
NewMass Affluent Banking in the Middle East – Regional Breakdown by Market Trends, Investment Preferences and Competitor Benchmarking
This report analyzes the Middle East's mass affluent market. This includes overall mass affluent market size (number of individuals) and their distribution in the region. The report provides analysis of the factors driving affluence and examines mass affluent individuals’ financial goals, banking patterns, investment preferences, and insurance preferences. The report also covers the region's competitor benchmarking and case studies. Based on the consumer profiles covered in this report a few general results can be gleaned. For example, compared to the...
-
Consumer Insights
NewMass Affluent Banking in Western Europe – Regional Breakdown by Market Trends, Investment Preferences and Competitor Benchmarking
This report analyzes Western Europe’s mass affluent market, including overall mass affluent market size (number of individuals) and their distribution in the region. The report provides analysis of the factors driving affluence and examines mass affluent individuals’ financial goals, banking patterns, investment preferences, and insurance preferences. The report also covers the region's competitor benchmarking and case studies. Based on the consumer profiles covered in this report, a few general results can be gleaned. For example, most customers conduct their banking...
-
Sector Analysis
NewData Centers 2.0 – Transforming Tomorrow’s Compute
As the digital landscape evolves, the role and design of data centers are undergoing a profound transformation. "Data Centers 2.0: Transforming Tomorrow's Compute" illuminates the cutting-edge technologies and innovations redefining this space. Central to this transformation is the integration of advanced network services virtualization, grid computing, and hybrid cloud management, alongside pioneering cooling systems and power management solutions. These advancements not only enhance the efficiency and scalability of data centers but also address the increasing environmental concerns associated with their...
-
Company Insights
New1Drop Diagnostics Pipeline Insight and Competitive Landscape, 2024
Empower your strategies with our 1Drop Diagnostics Pipeline Insight and Competitive Landscape, 2024 report and make more profitable business decisions. 1Drop Diagnostics offers best techniques from microfluidics, biochemistry, photonics and information technology to build high performance point-of-care diagnostics devices. GlobalData's Medical Devices company profile report, “1Drop Diagnostics Pipeline Insight and Competitive Landscape, 2024" provides information about the company overview and analysis on their pipeline products. This company profile report provides key information and data related to: Top level information about...
-
New
Net Present Value Model: Acelyrin Inc’s Izokibep
Empower your strategies with our Net Present Value Model: Acelyrin Inc's Izokibep report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s Ulevostinag
Empower your strategies with our Net Present Value Model: Merck & Co Inc's Ulevostinag report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: GSK plc’s Belrestotug
Empower your strategies with our Net Present Value Model: GSK plc's Belrestotug report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: AstraZeneca Plc’s Anselamimab
Empower your strategies with our Net Present Value Model: AstraZeneca Plc's Anselamimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Eli Lilly and Co’s Eltrekibart
Empower your strategies with our Net Present Value Model: Eli Lilly and Co's Eltrekibart report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Avalo Therapeutics Inc’s Quisovalimab
Empower your strategies with our Net Present Value Model: Avalo Therapeutics Inc's Quisovalimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.